NSCLC Drug Universe Expands: Genentech's Alecensa OK'd
This article was originally published in Scrip
Executive Summary
The universe seems to be working this year in favor of patients with non-small-cell lung cancer (NSCLC) – with a lot of help from drug makers and the FDA's Office of Hematology and Oncology Products.